Pomalidomide is a next-generation immunomodulatory agent with activity in relapsed light chain (AL) amyloidosis, but real world outcomes are lacking. We report the experience of the UK National Amyloidosis Centre. All patients with AL amyloidosis treated with pomalidomide between 2009 and 2017 were included. Data was collected on treatment toxicity and clonal response. Survival was calculated by the Kaplan-Meier method and outcomes reported on an intent-to-treat (ITT) basis. A total of 29 patients treated with pomalidomide were identified. Haematological responses at 3 months were: complete response (CR) nil, very good partial response (VGPR) 10 (35%), partial response (PR) 9 (31%), stable or progressive disease 7 (24%), unevaluable 3 (10%). On an ITT basis (n = 28), responses at 6 months were: CR-nil, VGPR-11 (39%), PR-2 (7%) and the remaining patients were non-responders 15 (53%). Median overall survival was 27 months (95% confidence interval 15Á7-38Á1 months). Median progression free survival (PFS) was 15 months (95% confidence interval 6Á24-23Á77). In conclusion, pomalidomide has activity in patients with relapsed AL amyloidosis. Responses are rapid and early responses may be predictive of a sustained overall response. Deep responses (VGPR or better) are seen in only a third of all patients and combination therapy needs to be explored.
Systemic AL amyloidosis is a plasma cell disorder characterised by the deposition of monoclonal immunoglobulin light chains in the form of amyloid fibrils leading to progressive organ dysfunction. Most patients present with advanced organ involvement, which has a poor overall survival (OS). The survival of patients with systemic light chain (AL) amyloidosis has improved over the last decade, with a 4-year OS of 54% (2010-2014) compared to 31% (2000-2004) (Muchtar & Gertz, 2017) . This improvement is largely a consequence of the introduction of effective, novel treatment agents (Merlini et al, 2013) . More patients are surviving beyond first line treatment, reflected by a reduction in 6-month mortality (37% in 2000-2004, to 24% 2010-2014) (Muchtar & Gertz, 2017) . The disease course in AL amyloidosis now more closely resembles that of multiple myeloma, characterised by remission and subsequent relapse; hence there is a need for alternative effective lines of therapy at each relapse.
Since AL amyloidosis is characterised by significant organ dysfunction, treatment must not only be effective in terms of providing a deep and rapid clonal haematological response, but also be minimally toxic to prevent any worsening of organ function. Most patients are treated with a proteasome inhibitor-based treatment in the front line setting, and a recent phase III trial has shown clear superiority of this approach over alkylator-based treatment (Kastritis et al, 2016) . However, there is no standardised pathway for the treatment of relapsed disease. The immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide) have a role in the treatment of patients with AL amyloidosis who relapse after front line treatment. Single agent thalidomide has poor tolerance and limited efficacy (Palladini et al, 2005) . Thalidomide combined with cyclophosphamide or melphalan has reasonable activity but toxicity remains high (Jelinek et al, 2016) . Lenalidomide has an improved toxicity profile and is research paper better tolerated when used at doses of 15 mg per day, with overall haematological response rates ranging from 41% to 67%, and is widely used as a second line agent in combination with dexamethasone (Dispenzieri et al, 2007; Sanchorawala et al, 2007) .
Pomalidomide is a next generation immunomodulatory agent that is licenced for the treatment of myeloma patients who have relapsed after treatment with lenalidomide. Pomalidomide has been reported in AL amyloidosis in three early phase trials with much better tolerance then lenalidomide and thalidomide Sanchorawala et al, 2016; Palladini et al, 2017) . Experience of this drug outside of a trial setting is however limited.
We describe the outcome of 29 patients with systemic AL amyloidosis, treated at the UK National Amyloidosis Centre (NAC), with a pomalidomide-based regime.
Materials and methods
All patients treated with pomalidomide between 2009 and 2017 were identified from the UK NAC database. Six patients were excluded because pomalidomide was initiated prior to assessment at the NAC, or the patients were lost to followup, leaving 29 patients eligible for analysis. Diagnosis of amyloidosis was confirmed on a tissue biopsy by demonstration of characteristic birefringence under cross polarized light with Congo-red staining, and AL typing was confirmed by immunohistochemistry with specific antibodies or by mass spectrometry. All patients had detailed baseline assessment for organ function, imaging and biomarker assessments. The starting dose of pomalidomide was 4 mg daily (days 1-21 in a 28-day cycle) with weekly dexamethasone 20-40 mg. Monthly data was collected on treatment, toxicity and clonal response. Organ involvement was defined according to the international amyloidosis consensus criteria (Gertz et al, 2005) . Haematological and organ responses were defined according to the international amyloidosis consensus criteria . Organ responses were assessed from the time of starting pomalidomide to the end of therapy (Gertz et al, 2005; Comenzo et al, 2012) . The primary outcomes were haematological responses (HR) and OS following pomalidomide treatment. Overall survival was defined as time in months from start of pomalidomide treatment to death from any cause. Secondary outcomes included: progression-free survival (PFS), calculated from start of pomalidomide therapy to haematological progression, need for second line treatment or death. Outcomes are reported on an intent-to-treat (ITT) basis.
Statistical analysis was performed using SPSS version 21 (IBM Corporation, Armonk, NY, USA). Approval for analysis and publication was obtained from the institutional review board at the University College London, and written consent was obtained from all patients in accordance with the Declaration of Helsinki. Survival outcomes were analysed using the Kaplan-Meier method, with comparisons done using the log rank test. All P-values were two sided with a significance level of <0Á05.
Results
A total of 29 patients were included in this study. The patient baseline characteristics are listed in Table I . The median number of organs involved was 3 (range 1-6) with renal, cardiac and liver involvement in 65Á5%, 69Á0% and 20Á7% of patients respectively. All patients had relapsed disease. The median number of lines of prior treatment was 4 (range 1-7). Twenty six (90%) patients had received prior bortezomib and 24 (83%) and 10 (35%) patients had received prior lenalidomide and thalidomide respectively. Seven percent of patients were refractory to bortezomib, 10% were refractory to lenalidomide and 3% to both therapies. The standard dose of pomalidomide was 4 mg daily, with 20 mg of dexamethasone given weekly. In six patients pomalidomide was started at a lower dose, (3 mg in 3 patients, 2 mg in 2 patients and 1 mg in 1 patient), due to frailty and pre-existing cytopenias. The median number of cycles of pomalidomide was 4 (range 1-24) and median duration on pomalidomide was 5 months (range 1-29). Median duration of treatment was 7 months (range 2-25) for non-responders (stable or progressive disease), and 4 months (range 3-29) for responders (partial response or better). The median N-terminal pro-brain natriuretic peptide (NT-proBNP) increased in 75% of the patients on pomalidomide, from a median of 7800 ng/l (range 144-77 585 ng/l) to 14 690 ng/l (range 447-155 161 ng/l) at a median of 4 months of pomalidomide therapy.
Haematological responses were rapid with one patient achieving a complete response (CR) and eight patients achieving a very good partial response (VGPR) by the end of one cycle. Haematological responses achieved by the end of 3 cycles of treatment were: CR-nil, VGPR 10 (34Á5%), partial response (PR) 9 (31Á0%), stable or progressive disease 7 (24Á1%). Three patients were not evaluable owing to missing light chain measurements. The median time to best response was 3 months (range 1-6). The final response assessment was done at end of 6 months (missing data on one patient). On an ITT basis (n = 28) at 6 months, no patients were in a CR, 11 (39%) had achieved a VGPR, 2 (7%) had a partial response and the remaining patients had stable or progressive disease (i.e. non-responders -53%) (Fig 1) . However, of the patients who had achieved a VGPR at 3 months, only 2 patients had progressed by 6 months. Of the patients not achieving a VGPR or better by 3 months, only one additional patient achieved a VGPR at 6 months. There was no impact of prior bortezomib or lenalidomide exposure on depth of response.
Given that cardiac response was assessed by NT-proBNP values, to minimise the impact of the increase in NTproBNP with pomalidomide treatment, we evaluated organ responses at 6 months and also at the end of pomalidomide treatment. Of the 20 patients with cardiac involvement, 13 patients were evaluable at 6 months (the remaining 4 patients had NT-proBNP <650 ng/l and 3 others had missing NT-proBNP values). Of these patients, 38% (5/13) had a cardiac response and 46% (6/13) had cardiac progression; and 15% (2/12) were non-responders. At the end of pomalidomide treatment 14 patients were evaluable: 43% (6/14) with a cardiac response, 29% (4/14) with cardiac progression and 29% patients (4/14) were non-responders. Only one additional patient therefore achieved a cardiac response after stopping pomalidomide and so there was only a small actual bias introduced by the increase in NT-proBNP on response assessment. The median time to reach a cardiac response was 7 months (3-9 months).
Of the 19 patients with renal involvement, four patients were established on dialysis prior to pomalidomide and one patient died before repeat creatinine readings were taken, leaving 14 patients eligible for analysis. Seven patients had a 25% increase in their creatinine during pomalidomide therapy, but only one patient went on to require renal replacement therapy. For the remaining six patients, the renal function of two has continued to deteriorate after stopping pomalidomide therapy (but they remain dialysis-independent), one patient's renal function has improved, two patients have not had repeat creatinine readings (one due to death and the second due to no follow-up since stopping pomalidomide). Seven patients' creatinine readings remained stable on pomalidomide treatment, and no patients' creatinine readings improved. Renal response was assessed at 6 months. Renal progression was seen in 33% (3/9) and a renal response was seen in 44% (4/9) and no response in 22% (2/9) patients. All three patients with renal progression were non-responders, i.e. had stable or progressive disease. This suggests that these were true renal amyloid progression events, rather than pomalidomide-induced.
With a median follow-up of 13 months (2-37 months), there were 12 deaths. The median OS from start of pomalidomide was 27 months (95% confidence interval [CI] 20Á1-33Á9 months) (Fig 2) . The OS for patients achieving response PNS, peripheral nervous system; ANS, autonomic nervous system; NT-pro-BNP, N-terminal pro-brain natriuretic peptide. at 6 months was: VGPR or better 37 months, PR 27 months, non-responders 15 months, progressive disease 19 months (Fig 3) . The median PFS was 15 months (95% CI 6Á2-23Á8 months) (Fig 2) . The most common adverse events were: non-neutropenic infection (56%), lethargy (56%), sensory neuropathy (44%), neutropenia (33%), pain (33%), constipation (22%), diarrhoea (22%), fluid overload (22%), hypotension (11%), mucositis (11%), peripheral motor neuropathy (11%), rash (11%), somnolence (11%) and renal impairment (11%). According to the Common Toxicity Criteria for Adverse Events (CTCAE) version 4.03, the highest grade was 3 and the adverse events with this grade were: non-neutropenic infection (33%), neutropenia (22%), sensory neuropathy (22%), fatigue (11%) and fluid overload (11%). Nineteen patients have stopped pomalidomide treatment, 1 has died and 9 patients remain on ongoing therapy. The reason for discontinuing therapy was available in 17/19 (89%) of patients. Six patients (35Á2%) stopped pomalidomide due to a planned clinical decision, because the patient had reached an adequate haematological response. Seven (41Á1%) patients discontinued due to adverse events -one patient each due to: fatigue, worsening peripheral sensory neuropathy, renal impairment, worsening orthostatic hypotension and frailty, and patient preference in two cases. Four patients (23Á5%) discontinued pomalidomide due to stable or progressive disease and only two patients went on to receive a further line of therapy after pomalidomide, one with carfilzomib and the other with thalidomide-based therapy.
Discussion
This data demonstrates that pomalidomide has activity in patients with AL amyloidosis at relapse, with patients achieving a relatively rapid response by 3 months. Some patients, even in this heavily pre-treated patient population, achieved deep clonal responses of VGPR or better, however this realworld data suggests that, despite encouraging early responses, longer term benefits appear much less. A significant proportion of patients die or discontinue therapy, and there is a lack of persisting response with 52% having no response, died or progressed by 6 months.
There have been three previous phase 2 trials conducted with pomalidomide in the setting of AL amyloid, which are summarised in Table II . The OS of patients treated with pomalidomide is remarkably similar in all previous studies, (26-28 months; Dispenzieri et al, 2012; Sanchorawala et al, 2016; Palladini et al, 2017) , and the outcomes of this current cohort are comparable, with an OS of 27 months. Likewise, a PFS of 15 months in this current cohort is comparable to the previously reported PFS of 14-17Á8 months Sanchorawala et al, 2016; Palladini et al, 2017 ). In our current cohort, the overall response rate was similar to the Italian cohort (Palladini et al, 2017) at 3 months (66%). The Italian group however report best response at 7 cycles, which is very different from our cohort where median time to best response was 3 months. In our cohort, only one patient who had not Table II . A comparison of the three previous phase 2 trials of pomalidomide in AL amyloidosis, the Mayo group ) the Boston group (Sanchorawala et al, 2016 ) the Italian group (Palladini et al, 2017) and the data presented here from the NAC. Dispenzieri et al (2012) n (%) Sanchorawala et al (2016) n (%) Palladini et al (2017) (48) 12 (50) 17 (61) 13 (46 achieved a VGPR by 3 months improved depth of response and, indeed, two patients with VGPR at 3 months had progressed by 6 months. This suggests that early response predicts the longer-term response and that prior therapy may affect the durability of haematological responses. Interestingly, this is similar to our previous data using risk-adapted cyclophosphamide, thalidomide and dexamethasone, where we found very few responses beyond 3 months and this resulted in a change in clinical practice at our centre, reviewing therapy at 3 months to add/switch to an alternative agent (Wechalekar et al, 2007 ). It appears intriguing that pomalidomide, which has structural similarity to thalidomide (and lenalidomide), appears to show a similar pattern. Two factors may be limiting the duration of response in our cohort compared to the previous studies: the majority of our patients had prior immunomodulatory drug-based treatment and the standard practice in the UK is for patients to receive a fixed duration of treatment. A quarter of patients in the current series had planned discontinuation of treatment after achieving a haematological response. Almost all studies with pomalidomide in AL and in myeloma have used continuous therapy and so there is limited data on progression after stopping pomalidomide. Based on data from previous AL studies with other regimes (Wechalekar et al, 2007) , we know that patients can remain in a stable haematological response even after discontinuing therapy -indeed in the current cohort, of the 6 patients who stopped therapy in a planned manner, 2 relapsed and 4 are still in remission. This suggests that discontinuation of pomalidomide could considered in some patients after achieving a deep response, where tolerance may be a problem.
The toxicity profile of pomalidomide when used in myeloma is favourable: in a recent pooled analysis of 1088 myeloma patients only 9Á7% of patients had to discontinue pomalidomide therapy, with myelosuppression most commonly reported (Jelinek et al, 2016) . In AL amyloidosis, this is remarkably different with discontinuation rates of 60-93% in the previous studies Sanchorawala et al, 2016; Palladini et al, 2017) . In our cohort, 38Á9% were unable to tolerate therapy, with side effects ranging from fatigue to worsening of neuropathy and orthostatic hypotensionconsistent with previously reported data (Table II) . A limiting feature of this series is that of a retrospective series in capturing true adverse event data-the reported number is likely to be an under-representation of the true toxicity of pomalidomide.
In conclusion, pomalidomide combined with dexamethasone is a useful treatment option for patients with AL amyloidosis with relapsed refractory clonal disease. A significant proportion of patients achieve good haematological responses, however responses are not as deep nor as durable in the real world setting. Responses are rapid and early responses appear to define longer-term outcomes. Pomalidomide is not as well tolerated in AL amyloidosis as myeloma and careful dose titration of pomalidomide may allow more patients to remain in therapy. Combination studies of pomalidomide with other agents like proteasome inhibitors or Venetoclax may offer additional and deeper responses and needs future prospective studies.
